Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 241-248 , April 2009

Statin Therapy and Clinical Outcomes in Heart Failure: A Propensity-Matched Analysis

  • Maral Ouzounian, MD

      Affiliations

    • Heart & Stroke/Richard Lewar Centre for Excellence, University of Toronto, and Division of Cardiology, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • ,
  • Jack V. Tu, MD, PhD

      Affiliations

    • Heart & Stroke/Richard Lewar Centre for Excellence, University of Toronto, and Division of Cardiology, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Divisions of General Internal Medicine and Cardiology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Peter C. Austin, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Departments of Public Health Sciences and Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
    • ,
  • Alice Chong, BSc

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • ,
  • Peter P. Liu, MD

      Affiliations

    • Heart & Stroke/Richard Lewar Centre for Excellence, University of Toronto, and Division of Cardiology, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    • Canadian Institutes of Health Research, Ottawa, Ontario, Canada
    • ,
  • Douglas S. Lee, MD, PhD

      Affiliations

    • Heart & Stroke/Richard Lewar Centre for Excellence, University of Toronto, and Division of Cardiology, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests: Douglas S. Lee, MD, PhD, Institute for Clinical Evaluative Sciences, 2075 Bayview Ave Rm G-106, Toronto, Ontario, M4N 3M5 Canada.

Received 2 May 2008 ,Revised 9 October 2008 ,Accepted 21 October 2008.

References 

  1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–1009
  2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  3. MRC/BHF. Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33
  4. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. ASCOT Inverstigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  5. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–2261
  6. Investigators GISSI-HF. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372:1231–1239
  7. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–2587
  8. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22(4 suppl A):6A–13A
  9. Lipinski MJ, Abbate A, Fuster V, Vetrovec GW. Drug insight: statins for nonischemic heart failure–evidence and potential mechanisms. Nat Clin Pract Cardiovasc Med. 2007;4:196–205
  10. Raina A, Pickering T, Shimbo D. Statin use in heart failure: a cause for concern?. Am Heart J. 2006;152:39–49
  11. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004;43:1439–1444
  12. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society. Altered thyroid hormone metabolism in advanced heart failure. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation. 2005;112:e154–e235
  13. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–269
  14. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259
  15. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Services, US Department of Health and Human Services; 1988;
  16. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441–1446
  17. Juurlink D, Preyra C, Croxford R, Chong A, Austin P, Tu J, et al. Canadian Institute for Health Information Discharge Abstract Database: a Validation Study. Toronto, Ontario: Institute for Clinical Evaluative Sciences. 2006;
  18. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J. 2002;144:290–296
  19. Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43:182–188
  20. Ghali WR, Quan H, Brant R, van Melle G, Norris CM, Faris PD, et al. Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA. 2001;286:1494–1497
  21. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26:734–753
  22. Rosenbaum PR, Rubin DB. Difficulties with regression analyses of age-adjusted rates. Biometrics. 1984;40:437–443
  23. Austin PC. The performance of different propensity score methods for estimating marginal odds ratios. Stat Med. 2007;26:3078–3094
  24. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006;25:2084–2106
  25. Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54:387–398
  26. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281
  27. Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6:635–641
  28. Ray JG, Gong Y, Sykora K, Tu JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med. 2005;165:62–67
  29. Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, Krumholz HM. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006;113:1086–1092
  30. Folkeringa RJ, Van Kraaij DJ, Tieleman RG, Nieman FH, Pinto YM, Crijns HJ. Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail. 2006;12:134–138
  31. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006;296:2105–2111
  32. Austin PC, Mamdani MM, Stukel TA, Anderson GM, Tu JV. The use of the propensity score for estimating treatment effects: administrative versus clinical data. Stat Med. 2005;24:1563–1578
  33. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Polonski L, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol. 2006;97:899–904
  34. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332–337
  35. Laufs U, Wassmann S, Schackmann S, Heeschen C, Bohm M, Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol. 2004;93:103–108
  36. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108:839–843
  37. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004;94:1306–1310
  38. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005;112:357–363
  39. Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000;102:611–616
  40. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42:1933–1940
  41. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8:216–224
  42. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361:1077–1083
  43. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356:930–933
  44. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18(suppl):S137–S144
  45. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial?. J Am Coll Cardiol. 2002;39:1567–1573
  46. Lloyd-Williams F, Mair F, Shiels C, Hanratty B, Goldstein P, Beaton S, et al. Why are patients in clinical trials of heart failure not like those we see in everyday practice?. J Clin Epidemiol. 2003;56:1157–1162
  47. Mcmurray J. Heart failure: we need more trials in typical patients. Eur Heart J. 2000;21:699–700
  48. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002;162:1689–1694
  49. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377–1384

 The Institute for Clinical Evaluative Sciences is supported in part by a grant from the Ontario Ministry of Health and Long-Term Care. The opinions, results and conclusions are those of the authors and no endorsement by the Ministry of Health and Long-Term Care or by the Institute for Clinical Evaluative Sciences is intended or should be inferred. This study was supported by an operating grant from the Canadian Institutes of Health Research (CIHR) and a CIHR Team Grant in Cardiovascular Outcomes Research. M. Ouzounian is supported by a 2007 Research Fellowship Award from the Heart Failure Society of America and the Tailored Advanced Collaborative Training in Cadiovascular Sciences program of the CIHR; J. V. Tu is a Career Investigator of the Heart & Stroke Foundation of Ontario and Canada Research Chair in Health Services Research; P. P. Liu holds the Heart & Stroke/Polo Chair Professor of Medicine and Physiology at the University Health Network, University of Toronto and is Scientific Director, Institute of Circulatory and Respiratory Health, CIHR; P. C. Austin is supported by a New Investigator Award from the CIHR; D. S. Lee is a clinician-scientist of the CIHR.

 A preliminary version of the data in this manuscript was presented at the Scientific Sessions of the American Heart Association, November 5, 2007, in Orlando, Florida.

PII: S1071-9164(08)01050-6

doi: 10.1016/j.cardfail.2008.10.026

Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 241-248 , April 2009

Article Tools

* Image Usage & Resolution